The feasibility, acceptability, and effectiveness of electronic patient-reported outcome symptom monitoring for immune checkpoint inhibitor toxicities: a systematic …
J Lai-Kwon, JE Cohen, K Lisy, C Rutherford… - JCO Clinical Cancer …, 2023 - ascopubs.org
PURPOSE Increasing use of immune checkpoint inhibitors (ICIs) in routine cancer care will
increase the incidence of immune-related adverse events (irAEs). Systems are needed to …
increase the incidence of immune-related adverse events (irAEs). Systems are needed to …
Arthralgia adverse events due to immune-checkpoint inhibitors for lung cancer patients: a systematic review and meta-analysis
D Zou, X Wang, Y Sun, X Wang, C Lu, A Wang… - Frontiers in …, 2023 - frontiersin.org
Background Immune agents targeting Programmed cell death-1 (PD-1) are a new type of
cancer treatment drugs. By inhibiting the interaction between PD-1 and PD-L1, the ability of …
cancer treatment drugs. By inhibiting the interaction between PD-1 and PD-L1, the ability of …
Analysis of a remote monitoring program for symptoms among adults with cancer receiving antineoplastic therapy
Importance Electronic patient-reported outcomes (ePROs) may have the potential to improve
cancer care delivery by enhancing patient quality of life, reducing acute care visits, and …
cancer care delivery by enhancing patient quality of life, reducing acute care visits, and …
[HTML][HTML] Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer …
EB Garon, BC Cho, A Luft, J Alatorre-Alexander… - Lung Cancer, 2023 - Elsevier
Objectives In the phase 3 POSEIDON study, first-line tremelimumab plus durvalumab and
chemotherapy significantly improved overall survival and progression-free survival versus …
chemotherapy significantly improved overall survival and progression-free survival versus …
Mobile app activity engagement by cancer patients and their caregivers informs remote monitoring
R Yunis, SJ Fonda, S Aghaee, A Kubo, SW Davis… - Scientific Reports, 2024 - nature.com
Abstract Mobile phone applications (“apps”) are potentially an effective, low-burden method
to collect patient-reported outcomes outside the clinical setting. Using such apps …
to collect patient-reported outcomes outside the clinical setting. Using such apps …
[HTML][HTML] Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II …
AM da Silva Lopes… - JMIR research …, 2023 - researchprotocols.org
Background: Management of severe symptomatic immune-related adverse events (IrAEs)
related to immune checkpoint inhibitors (ICIs) can be facilitated by timely detection. As …
related to immune checkpoint inhibitors (ICIs) can be facilitated by timely detection. As …
[HTML][HTML] Correlation Between Remote Symptom Reporting by Caregivers and Adverse Clinical Outcomes: Mixed Methods Study
I Oakley-Girvan, R Yunis, SJ Fonda, M Longmire… - Journal of Medical …, 2023 - jmir.org
Background Timely collection of patient-reported outcomes (PROs) decreases emergency
department visits and hospitalizations and increases survival. However, little is known about …
department visits and hospitalizations and increases survival. However, little is known about …
First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis
L Yi, Z Zhou, X Zeng, C Tan, Q Liu - Frontiers in Immunology, 2024 - frontiersin.org
Objective To determine the cost-effectiveness of imported immune checkpoint inhibitors
(ICIs) such as atezolizumab and durvalumab, and domestic ICIs like serplulimab and …
(ICIs) such as atezolizumab and durvalumab, and domestic ICIs like serplulimab and …
Integrating Patient-Reported Outcomes Into the Care of People With Advanced Cancer—A Practical Guide
J Lai-Kwon, E Thorner, C Rutherford… - American Society of …, 2024 - ascopubs.org
Patient-reported outcomes (PROs) are being increasingly integrated into routine clinical
practice to enhance individual patient care. This has been driven by recognition of the …
practice to enhance individual patient care. This has been driven by recognition of the …
Comparison Between Sotorasib with Docetaxel for the Treatment of Chinese Patients with Previously Treated NSCLC with KRASG12C Mutation: A Cost-Effectiveness …
L Yi, X Zeng, Z Zhou, Q Liu - Advances in Therapy, 2024 - Springer
Introduction This study sought to investigate the affordable price of sotorasib among patients
with previously treated advanced KRASG12C-mutant non-small cell lung cancer (NSCLC) …
with previously treated advanced KRASG12C-mutant non-small cell lung cancer (NSCLC) …